In preclinical studies, mutations of EGFR correlated with VEGF in lung cancer, as it has been shown that EGFR-mutant NSCLC cells hasten the expression of VEGF more than wild-type NSCLC cells [53]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.